TOKYO -- Cynata Therapeutics will start clinical trials in Japan and the U.S. on a stem-cell-based treatment for transplant patients under a licensing agreement with Fujifilm Holdings, the Australian medical venture's CEO said Friday.
The agreement with Fujifilm, which holds a 10%-plus stake in Cynata, will be signed this fiscal year, with clinical trials to enter their second phase in fiscal 2019, Ross Macdonald told reporters.
